Join
Live feed
·
PRReleasevia Quantisnow
Wave Life Sciences Ltd. logo

Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

ByQuantisnow·Wall Street's wire, on your screen.
WVE· Wave Life Sciences Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track WVE (Wave Life Sciences Ltd.) and more on Quantisnow.